LIVER CANCER

Combined TACE and sorafenib for HCC treatment

Transarterial chemoembolization (TACE) and sorafenib have both been shown to prolong survival in patients with unresectable hepatocellular carcinoma (HCC), but previous trials assessing the combination of TACE and sorafenib have been unable to show clinical benefit compared with TACE alone. Now, Kudo et al. report results from a randomized, multicentre prospective trial of TACE plus sorafenib compared with TACE alone in patients with unresectable HCC. Patients were randomized either to treatment with TACE plus sorafenib before and after TACE (n = 80) or to a group that received TACE without addition of sorafenib (n = 76). Median progression-free survival was significantly longer (P = 0.006) in the combination group (25.2 months) than in the TACE without sorafenib group (13.5 months). Median time to untreatable progression (a TACE-specific endpoint) was also significantly longer (P = 0.02) in the combination group (26.7 months) than in the TACE without sorafenib group (20.6 months).

References

Original article

  1. Kudo, M. et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut https://doi.org/10.1136/gutjnl-2019-318934 (2019)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jordan Hindson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hindson, J. Combined TACE and sorafenib for HCC treatment. Nat Rev Gastroenterol Hepatol 17, 66 (2020). https://doi.org/10.1038/s41575-020-0265-0

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing